Lv41
780 积分 2023-02-23 加入
A patent review of mutant-selective PI3Kα inhibitors for the treatment of different cancers (2021 - 2025)
3天前
已完结
Structural and Physicochemical Features of Oral PROTACs
5天前
已完结
PROTACs: past, present and future
7天前
已完结
Chemistries of bifunctional PROTAC degraders
7天前
已完结
Property-based optimisation of PROTACs
7天前
已完结
Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4/6 inhibitors: A comprehensive review
14天前
已完结
PROTAC Cell Permeability and Oral Bioavailability: A Journey Into Uncharted Territory
1个月前
已完结
PROTAC Cell Permeability and Oral Bioavailability: A Journey Into Uncharted Territory
1个月前
已关闭
Biologic degraders push forward in the clinic
2个月前
已完结
Dual-target ligand discovery for Alzheimer’s disease: triphenylphosphoranylidene derivatives as inhibitors of acetylcholinesterase and β-amyloid aggregation
4个月前
已关闭
皖公网安备34019202002308
